Cargando…

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study

BACKGROUND: Among HIV-1 infected patients who achieved virologic suppression, the use of atazanavir without pharmacologic boosting is debated. We evaluated the efficacy and tolerance of maintenance therapy with unboosted atazanavir in clinical practice. METHODS AND RESULTS: This multicenter retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hocqueloux, Laurent, Choisy, Philippe, Le Moal, Gwenaël, Borsa-Lebas, Françoise, Plainchamp, David, Legac, Eric, Prazuck, Thierry, de la Tribonnière, Xavier, Yazdanpanah, Yazdan, Parienti, Jean-Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494679/ https://www.ncbi.nlm.nih.gov/pubmed/23152890 http://dx.doi.org/10.1371/journal.pone.0049289

Ejemplares similares

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Finger-Stick Whole Blood HIV-1/-2 Home-Use Tests Are More Sensitive than Oral Fluid-Based In-Home HIV Tests
por: Jaspard, Marie, et al.
Publicado: (2014)

Impact de la prévalence du COVID-19 des personnels d’établissements médicosociaux sur le risque d’infection des résidents : étude prospective dans 17 EHPAD et MAS
por: Sève, A., et al.
Publicado: (2020)

Pooling Rectal, Pharyngeal, and Urine Samples to Detect Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium Using Multiplex Polymerase Chain Reaction Is as Effective as Single-Site Testing for Men Who Have Sex With Men
por: Prazuck, Thierry, et al.
Publicado: (2022)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS
por: Khan, Saif Ahmad, et al.
Publicado: (2020)

Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2018)

Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort
por: Postorino, Maria Concetta, et al.
Publicado: (2017)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Incidence and risk factors for medical care interruption in people living with HIV in a French provincial city
por: Fournier, Anna Lucie, et al.
Publicado: (2020)

Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV
por: Chu, Jennifer, et al.
Publicado: (2011)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir
por: Beckman, Joshua A., et al.
Publicado: (2017)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents
por: Ngara, Bernard, et al.
Publicado: (2020)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano, Roberto, et al.
Publicado: (2013)

Ureteral Obstruction Due to Radiolucent Atazanavir Ureteral Stones
por: Grant, Michael T., et al.
Publicado: (2017)

Atazanavir Crystal–Induced Chronic Granulomatous Interstitial Nephritis
por: Varghese, Vipin, et al.
Publicado: (2020)

Atazanavir/efavirenz/lamivudine: Covid-19: case report
Publicado: (2021)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
por: Avihingsanon, A, et al.
Publicado: (2010)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
por: van Lunzen, Jan, et al.
Publicado: (2016)

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice
por: Gantner, Pierre, et al.
Publicado: (2016)

Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review
por: Saint-Lary, Laura, et al.
Publicado: (2022)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
por: Smith, Kimberly Y, et al.
Publicado: (2008)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
por: Esker, S, et al.
Publicado: (2010)

Long-term treatment of patients with HIV-1: the role of atazanavir
por: Artacho, Miguel Ángel, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_dpemcta5vfb1832n1v67e5o30d